Advancing therapies for rare and underserved diseases

Todd C. Davis

Todd C. Davis has more than 30 years of operational and investment experience in the pharmaceutical and life science industries. He has led over $3 billion in healthcare deals including growth equity, structured debt and royalty acquisitions throughout his career. Mr. Davis has also led, structured and closed more than 40 intellectual property licenses, as well as hybrid royalty-debt deals. Prior to Benuvia, he held senior leadership roles at RoyaltyRx Capital, Healthcare Royalty Partners and Apax Partners. Previously, he held general management, business development, and licensing roles at Elan Pharmaceuticals and commercial and operational roles at Abbott Laboratories.

Mr. Davis is a Navy veteran, holds an MBA from Harvard University, and a BS from the U.S. Naval Academy. He currently serves on the board of BioDelivery Sciences International, Ligand Pharmaceuticals and Palvella Therapeutics.

Thrimoorthy Potta, PhD

Dr. Thrimoorthy Potta has over 15 years of branded and generic pharmaceutical product development leadership experience across a broad range of technologies and dosage forms. As Benuvia’s VP, Research & Development, he leads all operations in the development of liquid orals, sublingual sprays, intranasal sprays, inhalation aerosols, and solid dosage forms, from inception to product launch. Dr. Potta’s team has launched several drug products and managed the submission of several INDs and NDAs. Prior to Benuvia, Dr. Potta held R&D leadership positions at some of the most successful generic pharmaceutical companies, including Sun Pharmaceutical Industries Ltd. and Gland Pharma, Ltd. He has authored and co-authored more than 20 peer-reviewed publications and has several patents. Dr. Potta earned his Masters in Pharmaceutical Chemistry, his Ph.D. in Pharmaceutics and conducted his post-doctoral research in Chemical Engineering at Arizona State University. He serves as an Editorial Advisory Board Member of Recent Patents on Drug Delivery & Formulation.

Karon J. Morell

Karon J. Morell’s professional career spans over 50 years with 27 of them in executive leadership roles in the biotech, tissue, medical and pharmaceutical industries. Ms. Morell has deep compliance, clinical, regulatory, quality affairs, manufacturing, and technical operational expertise. Over the course of her career, she has successfully led diverse teams globally, achieved international agency product and facility approvals and has never received a U.S. FDA or International FDA inspection observation or finding.

Prior to Benuvia, Ms. Morell held senior positions in  compliance, regulatory, quality affairs and operations for Suneva Medical and its predecessor company for 12 years. During her tenure at the firm, Ms. Morell was responsible for the oversight of the company’s California corporate manufacturing facility for Artefill (now Bellafill) and its German facility which produced the critical raw component Polymethyl methacrylate (PMMA). Previously, Ms. Morell served as VP of Compliance, Regulatory, Quality Systems, Assurance & Control and as Tissue Bank Director at IsoTis Orthobiologics (now Integra LifeSciences). At IsoTis, she was instrumental in re-classifying some of the company’s biological human tissue products as medical devices. Prior to IsoTis, she held senior quality and regulatory roles at Medegen Medical Products, Nobel Biocare and Newport Medical Instruments.

Ms. Morell received a BS in Business Management from Southern California University.